samedan logo

 
 
spacer
home > ebr > spring 2003 > molecular medicine: targeting patients with the right treatment
PUBLICATIONS
European Biopharmaceutical Review

Molecular Medicine: Targeting Patients with the Right Treatment

How does Millennium define 'personalised medicine' and is the company using it today?


In the broadest sense, personalised medicine is the integration of diagnostic and evaluative procedures. From the earliest phase of drug discovery all the way through to clinical trials and the launch of a drug, personalised medicine is a way to get the right drug for the right patient at the right time. Millennium uses it across the board.

The clinical trials for Bortezomib (VelcadeTM) solution for injection, Millennium's novel drug ...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Allison Connolly, Biotechnology Reporter for the Boston Business Journal, talks to Dr Jeffrey Ross, Vice President for Molecular Medicine at Millennium Pharmaceuticals Inc


Dr Jeffrey Ross graduated from the Oberlin College and Buffalo School of Medicine. He was certified by the American Board of Pathology in 1974. Following this, Dr Ross served as Chief of Pathology at the Moncrief United States Army Hospital and was Professor at both Harvard Medical School and Massachusetts General Hospital.

In 1989 he became Professor and Chairman at the Albany Medical College and Pathologist-in-Chief at the Albany Medical Center Hospital. Dr Ross is Associate Editor for Basic Science of the American Journal of Clinical Pathology. He has served as Commissioner for graduate medical education of the American Society of Clinical Pathologists and serves on the scientific advisory boards of the Welch-Allyn Corporation, Tripath Oncology Inc and US Labs Inc.

In 1999 Dr Ross was named Scientific Fellow and Head of Molecular Pathology at Millennium Pharmaceuticals Inc, and became Vice President for Molecular Medicine in 2001.


spacer
Dr Jeffrey Ross
spacer
spacer
spacer
Allison Connolly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement